The therapeutic potential of ADAMTS8 in lung cancer patients without Immune checkpoint inhibitors/EGFR mutation
Y. Tsai (Kaohsiung, Taiwan), Y. Huang (Kaohsiung, Taiwan), C. Chang (Kaohsiung, Taiwan), L. Liu (Kaohsiung, Taiwan), K. Wu (Kaohsiung, Taiwan)
Source: International Congress 2022 – Identification of therapeutic strategies in lung cancer
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Tsai (Kaohsiung, Taiwan), Y. Huang (Kaohsiung, Taiwan), C. Chang (Kaohsiung, Taiwan), L. Liu (Kaohsiung, Taiwan), K. Wu (Kaohsiung, Taiwan). The therapeutic potential of ADAMTS8 in lung cancer patients without Immune checkpoint inhibitors/EGFR mutation. 1916
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|